drugset / Trial / NCT02296567
Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To demonstrate the effects of Lucentis (ranibizumab), Avastin ( bevacizumab), and Eylea ( aflibercept) on the levels of naturally occurring Vascular Endothelial Growth Factor (VEGF) in the systemic circulation of Age Related Macular Degeneration patients currently treated with these medications.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | — | Intravitreal |
| Comparator | Bevacizumab | Monoclonal antibody | — | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | — | Intravitreal |